FSC-2023
15.3.2023 16:48:34 CET | Business Wire | Press release
The second edition of the Financial Sector Conference (FSC 2023) opened today in Riyadh, welcoming over 3000 participants from around the world to discuss the way ahead for the global financial community under the conference theme of “Promising Financial Prospects.”
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230315005659/en/
Saudi Minister of Finance HE Mohammed Al-Jadaan addresses delegates at opening of Financial Sector Conference in Riyadh, Saudi Arabia (Photo: AETOSWire)
Welcoming delegates to the conference Saudi Minister of Finance HE Mohammed Al-Jadaan said: “I am confident that this conference will be an opportunity to build on experiences and share ideas to address a global economy which is full of challenges and opportunities—helping to make the global financial sector stronger, more influential and resilient.”
The conference opened with a powerful panel discussion examining the strategic options for the financial sector in light of challenging global economic circumstances. Credit Suisse Group AG Chairman Axel Lehmann told the audience: “What is clear is that over the past 10 to 15 years the massive geopolitical shifts we have seen are generating new economic opportunities in places like the Middle East which is becoming a vibrant new global centre along with places such as China and India.”
Commenting on opportunities emerging in Saudi Arabia, State Street Chairman and CEO Ronald O’Hanley added: “For investors it is clearly a very attractive time to be here with a strong economy and a Government that is committed to transition and powered by a well-educated workforce. There are clear investment opportunities in energy and renewables, in tourism and to benefit from the rise in the consumer economy.”
HE Eng. Khalid Al Falih, Saudi Arabia’s Minister of Investment, said: “We are now halfway to implementing Vision 2030 that will triple the scale of the economy and we are ahead of schedule but we know we cannot be complacent. One of the biggest shifts emerging is that in the past we were seen as a source of capital but that is being reversed today and we are urging the financial community to be aware of the opportunities and we aim to attract more capital and international partners.”
Alexandre Fleury, Co-Head of Market Activities, Societe Generale, told the conference: “Vision 2030 is extraordinary and an amazing achievement. But the world has not noticed enough what is happening in Saudi Arabia but soon investors will have no choice but to invest here. Global investors have to be a part of Vision 2030.”
Looking at the global economic situation, Seth Carpenter, Global Chief Economist, Morgan Stanley, “As Morgan Stanley, we are pretty optimistic about Asia, specifically China, Japan, India and Saudi Arabia. The weakest growth is in Europe and the US although economic performance is high. The quandary for central banks is how much you raise interest rates in order to bring inflation down; and judging exactly how much you need to slow things down without causing a recession.”
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230315005659/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Real Chemistry Announces New Asia Pacific Hub with Acquisition of Spurwing Communications in Singapore7.7.2026 01:00:00 CEST | Press release
Expanded footprint advances the company’s global strategy in key growth region for healthcare and pharma brands Real Chemistry, a global leader in AI- and insights-driven healthcare communications, today announced the acquisition of Spurwing Communications, establishing the company’s first Asia Pacific (APAC) strategic hub in Singapore. This milestone strengthens Real Chemistry’s global strategy and presence in APAC, enhancing its ability to support healthcare organizations. Combining deep market expertise with globally integrated capabilities across analytics, medical communications, advertising and strategic communications, the company is well positioned to deliver more connected, local insight-driven support — ultimately helping clients better reach and engage healthcare professionals, patients and caregivers across the region. “APAC is fast becoming one of the most dynamic and strategically important regions for healthcare innovation and access to life-improving therapies,” said Ka
Vertex to Acquire Crinetics Pharmaceuticals6.7.2026 22:04:00 CEST | Press release
- Crinetics adds potential best-in-class commercialized and Phase 3 endocrinology assets with ~$5 billion peak sales opportunity to Vertex’s portfolio - - PALSONIFY®, Crinetics’ recently launched, first and only, once-daily oral therapy for adults with acromegaly has demonstrated strong and growing early uptake - - Atumelnant, a once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist in Phase 3 development for congenital adrenal hyperplasia (CAH), has shown unique and transformative potential to both normalize androgen levels and enable management of patients with physiologic levels of glucocorticoids, the true goal of CAH management; atumelnant has also demonstrated therapeutic potential in patients with Cushing’s syndrome - - Acquisition adds to Vertex’s innovation pipeline, accelerates Vertex’s revenue growth and enhances long-term earnings profile - - Vertex to host investor call today, July 6 at 4:30 p.m. ET - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and C
Ciauru Wins the Second Edition of the Reply AI Music Contest, the International Competition Dedicated to Experimentation Across AI, Music and Live Performance6.7.2026 20:30:00 CEST | Press release
The winner was announced on the Kappa FuturFestival stage, following the performances of the five finalists selected by the international jury.German duo PARAFRAME & Avis Vox received the special Reply AI Studios Grand Prix award. The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706007611/en/ The second edition of the Reply AI Music Contest, the international competition created by Reply to explore new forms of expression combining artificial intelligence, music and live performance, concluded with the announcement of the winner on the Nova Stage powered by Reply during Kappa FuturFestival First place went to Ciauru, the stag
Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 20266.7.2026 15:00:00 CEST | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced it will report earnings after market close on July 30, 2026. The company will host a conference call and webcast on that date to discuss the second quarter 2026 results and the second half 2026 outlook at 5:00 p.m. Eastern / 2:00 p.m. Pacific time. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260706560476/en/ Rimini Street to Report Second Quarter 2026 Financial Results on July 30, 2026 A live webcast of the event will be available on Rimini Street’s Investor Relations site via the Rimini Street IR events link and directly via the webcast link. Dial-in participants can access the conference by dialing 1-800-836-8184. A replay of the webcast will be available for one year following the event. About Rimini Street, Inc. Rimini Street, Inc. (Nasda
Orion and Shilpa Medicare Expand Partnership to Develop and Supply Nivolumab Biosimilar for Europe6.7.2026 15:00:00 CEST | Press release
Shilpa Medicare Limited announced that its wholly owned subsidiary, Shilpa Biologicals Private Limited, has entered into a co-development and supply agreement with Orion Corporation for intravenous (IV) nivolumab biosimilar referencing one of the world’s most widely used cancer immunotherapies to widen patient access across Europe. Nivolumab helped usher in the era of immuno-oncology, transforming the outlook for patients with cancers such as melanoma and lung cancer. As the originator approaches loss of exclusivity in Europe, this partnership aims to put a high-quality, EU-GMP-manufactured nivolumab biosimilar within reach of more patients, reducing healthcare burden. In 2025, Nivolumab recorded sales of approximately USD4.1 billion (Source: IQVIA/IMS) Europe — underscoring the scale of the opportunity. Under the agreement, Orion will hold the exclusive rights to register, market, distribute and sell the nivolumab biosimilar across Europe. Shilpa Biologicals will lead product developm
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
